Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis

Onychomycosis of Toenail Clinical Trial

Official title:

Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04961684
• Other study ID #: 19E2407
• Status: Completed
• Phase: N/A
• Start date: February 10, 2020
• Est. completion date: September 22, 2020

Study information

• Verified date: July 2021
• Source: Oystershell NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The efficacy and safety of Solver Pen (prototype number X92001704) is evaluated in this randomized, open label, controlled, investigator-blinded, comparative clinical trial in 76 patients. Subjects are treated with either the test medical device (Solver Pen) or the comparator (Loceryl, 5% amorolfine), respectively, for a period of 90 days. The primary objective of the investigation is the increase of percentage of healthy surface on the great toenail at study end versus baseline, as evaluated by a blinded investigator. Patients are followed up for a period of 90 days, with visits at D0 (baseline), D30, D60 and D90, respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: September 22, 2020
• Est. primary completion date: September 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient having given her/his informed, written consent.

2. Patient cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.

3. Patient being psychologically able to understand information and to give their/his/her consent.

4. Age: more than 18 years.

5. Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement <2/3 of the tablet).

6. Patient with positive KOH staining.

7. Patient having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.

8. Women of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after study end.

Exclusion Criteria:

1. Pregnant or nursing woman or planning a pregnancy during the investigation;

2. Patient considered by the Investigator likely to be non-compliant with the protocol.

3. Patient enrolled in another clinical trial during the test period.

4. Subject having a known allergy to one of the constituents of the tested products.

5. Patient with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk;

6. Patient suffering from serious or progressive diseases (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology…

7. Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).

Related Conditions & MeSH terms

• Onychomycosis
• Onychomycosis of Toenail

Intervention

Device:
• Solver Pen
One application per day for 3 months

Drug:
• Loceryl 5%
One application per week for 3 months

Locations

Country	Name	City	State
Tunisia	Pr Doss office	Tunis

Sponsors (1)

Lead Sponsor	Collaborator
Oystershell NV

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of healthy surface (performance)	Variation of the percentage of healthy surface after 90 days of treatment with the test medical device or reference versus baseline value. Evaluation is done in blind by digital analysis of photographs of the great, infected toenail.	90 days
Secondary	Percentage of healthy surface (performance)	Variation of the percentage of healthy surface after 30 and 60 days of treatment with the test medical device or reference versus baseline. Blinded evaluation is performed by digital analysis of photographs of the great, infected toenail.	30 and 60 days
Secondary	Microbiological efficacy: KOH staining (performance)	Evaluation of microbiological efficacy of both treatments by KOH staining on D90 versus baseline.	90 days
Secondary	Microbiological efficacy: fungal culture (performance)	Evaluation of microbiological efficacy of both treatments by fungal culture on D90 versus baseline.	90 days
Secondary	Clinical efficacy: onychomycosis evolution (performance)	Blinded assessment of clinical efficacy of both treatments on D0 (baseline), D30, D60 and D90 by evaluation of onychomycosis evolution on a 4-point scale (failure to success)	30, 60 and 90 days
Secondary	Clinical efficacy: onycholysis (performance)	Blinded assessment of clinical efficacy of both treatments on D0 (baseline), D30, D60 and D90 by evaluation of onycholysis on a 5-point scale (none to severe)	30, 60 and 90 days
Secondary	Clinical efficacy: nail distrophy (performance)	Blinded assessment of clinical efficacy of both treatments on D0 (baseline), D30, D60 and D90 by evaluation of nail distrophy on a 5-point scale (none to severe)	30, 60 and 90 days
Secondary	Clinical efficacy: nail discoloration (performance)	Blinded assessment of clinical efficacy of both treatments on D0 (baseline), D30, D60 and D90 by evaluation of nail discoloration on a 5-point scale (none to severe)	30, 60 and 90 days
Secondary	Clinical efficacy: nail thickening (performance)	Blinded assessment of clinical efficacy of both treatments on D0 (baseline), D30, D60 and D90 by evaluation of nail thickening on a 5-point scale (none to severe)	30, 60 and 90 days
Secondary	Impact on quality of life (performance)	Evaluation of the impact on the quality of life (QoL) of the patients using a validated questionnaire (NailQoL: Nail Questionnaire Of Life from 0=no impact on life quality to 100=maximum impact on life quality) before (baseline) and 60 and 90 days of treatment with the test medical device or reference, respectively.	60 and 90 days
Secondary	Subjective evaluation questionnaire for the patient (performance)	Evaluation of efficacy, tolerance, and acceptability cosmetic aspect, usability…) of the investigational device by the patients using a subjective evaluation questionnaire (answers to questions with 5 modalities from "strongly disagree" to "strongly agree"), performed at each visit and at D14 (via phone).	14, 30, 60 and 90 days of treatment
Secondary	Assessment of local tolerance by the investigator (safety and tolerability)	Evaluation of local tolerance of the test medical device at each visit. Assessment is performed by the investigator via clinical evaluation and subject interrogation on a scale from 0 (bad tolerance) to 3 (very good tolerance)	30, 60 and 90 days
Secondary	Incidence of Adverse events (safety and tolerability)	Collection of Adverse events and adverse device effects throughout the study	30, 60 and 90 days